Celularity Inc. Receives Nasdaq Notice for Late Quarterly Filings, Working to Regain Compliance
Celularity Inc. (CELU) received a Nasdaq notice for late quarterly filings, failing to submit reports for Q1 and Q2 2026. The company has until September 4 to submit a compliance plan. Trading continues on Nasdaq under 'CELU'. Celularity is working to file the reports promptly.
How this was made
The 30-second read
Why it matters
The Nasdaq notice highlights a compliance breach that could affect liquidity and valuation.
Market read
Compliance risk may trigger short‑term price volatility for CELU.
What to watch
Potential for a waiver or extension from Nasdaq could mitigate downside.
Background
Celularity is a regenerative medicine company listed on Nasdaq Capital Market.
Ticker impact
Celularity received a Nasdaq notice for late 10-Q filings and must submit a compliance plan by Sep 4, 2026.
downside pressure until compliance is demonstrated
Listing non‑compliance creates uncertainty and may trigger short‑selling or sell‑offs.
Market effects
Regulatory compliance concerns may affect other small biotech listings.
Minimal impact on broader market.
Limited to investors in Celularity and similar micro‑caps.
Counterpoint
If Celularity resolves filings quickly, the notice may be priced in and present a buying opportunity.
Key entities
- CompanyCelularity Inc.
Subject of the Nasdaq compliance notice.
